Our
stock picking system has picked VLTS (Valentis Inc.) today. The simulation
software will buy this stock on
Jul
18, 2006 at OPEN price. Our Loss Stop
is at -28% Do not hold if stock drops more than 28%. Please visit us
tomorrow after 9 o'clock for the next move..
Please see the below signals for the next trading day
JULY 2006
Symbol
Alert Date
Entry Price
Exit Date
Exit Price
VOLUME
Profit/Loss
FORG
05-Jul-06
0.589
12-Jul-06
0.42
1046756
-28%
TOMO
07-Jul-06
13.92
14-Jul-06
13.95
4524542
0.2%
DNE
10-Jul-06
2.10
14-Jul-06
2.14
853300
1.9%
VLTS
17-Jul-06
BUY @ OPEN *
2924936
-
* Open entry is between 9:30 and 10:30. Do not enter before the
market opens.
* Modified
To see our recent history in 2006 please click here.
RECENT PERFORMANCE
Dec 2005
21.6%
Jan 2006
41%
Feb 2006
-3.9%
Mar 2006
90%
Apr 2006
283%
May 2006
54.7%
COMPANY INFORMATION
Valentis Inc.
863 A Mitten Road
Burlingame, CA 94010
United States
Phone: 650-697-1900
Fax: 650-652-1990
Web Site: http://www.valentis.com
Sector:
Healthcare
Industry:
Biotechnology
Full Time Employees:
19
Valentis, Inc., a biotechnology company, focuses on the creation of
cardiovascular therapeutics and associated delivery systems. It develops
products for peripheral arterial disease. Peripheral arterial disease is
a vascular occlusive disease of the lower extremities. The company has
developed a series of technologies, including gene delivery and
expression technologies, and proprietary formulation and manufacturing
technologies that enable the generation of therapeutics to treat a range
of diseases. Its primary products include VLTS 934, a Phase IIb testing
anti-inflammatory drug; DEL-1, an angiogenic protein that promotes the
formation of new blood vessels; and Deltavasc, which is a Phase IIa
clinical trial completed investigational product that incorporates the
DEL-1 gene to stimulate new blood vessel growth. The company also has 10
products in development by licensors of Valentis’ various technologies
to treat infectious diseases and cancer. In addition, it offers contract
services for process development and manufacturing, which include
microbial fermentation, protein/MAb purification, plasmid DNA
purification, process scale-up, and bacterial genetics. The company has
research and development collaborations principally with Roche Holdings,
Ltd.; Boehringer Ingelheim International GmbH; Eli Lilly & Company; and
Glaxo Wellcome plc. Valentis is headquartered in Burlingame, California.
SIMULATION
PERFORMANCE RESULTS HAVE INHERENT LIMITATIONS, THE PERFORMANCE
TABLES AND RESULTS ARE BASED ON BACKTESTING OF CERTAIN TRADING
STRATEGIES. DO NOT REPRESENT TRADING IN ACTUAL ACCOUNTS You may have more losses or profits in your account comparing to other
member accounts due to many factors, including but not limited to: you and
other people may trade stock picks in different orders, orders not get
filled or partially get filled, selective trading some specific stock picks
instead of all stock picks, paying different commission fees required by
different brokerages, stock positions entered and exited at different price
other than our suggested price due to market orders, order execution
delayed, various human decisions or technical failures.
You
may lose all of your money when investing and trading in the stock markets! The data contained in the reports within this site is provided for
informational purposes only. It should not be viewed as a solicitation for
the referenced system or vendor. While the information and statistics given
are believed to be complete and accurate, we cannot guarantee their
completeness or accuracy. As past performance does not guarantee future
results, these results may have no bearing on, and may not be indicative of,
any individual returns realized through participation in this or any other
investment. No part of this document should be considered apart from the
Disclosure Statements contained herein.